LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

NVO

119.89

+2.03%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

NVO

119.89

+2.03%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

NVO

119.89

+2.03%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

NVO

119.89

+2.03%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

NVO

119.89

+2.03%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

Inicio・Lista de Acciones・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Cerrado

Sector Salud

52.24 -0.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

52.63

Métricas clave
By Trading Economics
Ingresos	14B 1.7B
Ventas	300M 12B
P/B Media del Sector	14.05 113.916
BPA	2.07
Margen de beneficio	13.77
Empleados	34,100
EBITDA	13B 4.4B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	-3.97 downside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024
Fecha Próximo Dividendo	1 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	5.1B 109B
Apertura anterior	52.62
Cierre anterior	52.24

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

136 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

51.74 / 52.41 Soporte y Resistencia

Bristol-Myers Squibb Co. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 sept 2024, 13:06 UTC

Principales Movimientos del Mercado

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

26 jul 2024, 14:08 UTC

Ganancias

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26 jul 2024, 11:54 UTC

Ganancias

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25 abr 2024, 14:38 UTC

Ganancias

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

7 oct 2024, 14:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 oct 2024, 13:45 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 oct 2024, 11:54 UTC

Principales Noticias

Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 oct 2024, 09:30 UTC

Principales Noticias

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer's Windfall -- Heard on the Street -- WSJ

27 sept 2024, 18:36 UTC

Ganancias

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27 sept 2024, 09:15 UTC

Acciones populares

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

26 sept 2024, 23:20 UTC

Principales Noticias

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- Update

26 sept 2024, 22:56 UTC

Principales Noticias

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ

16 ago 2024, 11:30 UTC

Principales Noticias

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8 ago 2024, 10:30 UTC

Principales Noticias

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29 jul 2024, 10:30 UTC

Principales Noticias

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26 jul 2024, 14:51 UTC

Ganancias

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26 jul 2024, 13:53 UTC

Ganancias

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26 jul 2024, 11:28 UTC

Ganancias

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26 jul 2024, 11:14 UTC

Ganancias

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26 jul 2024, 11:06 UTC

Ganancias

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26 jul 2024, 11:06 UTC

Ganancias

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26 jul 2024, 11:04 UTC

Ganancias

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26 jul 2024, 11:04 UTC

Ganancias

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q EPS 83c >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19 jun 2024, 05:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 may 2024, 22:51 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 abr 2024, 12:36 UTC

Ganancias

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. Esperado

Precio Objetivo

By TipRanks

-3.97% caída

Estimación a 12 meses

Media 50.32 USD -3.97%

Máximo 60 USD

Mínimo 33.1 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

51.74 / 52.41Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

136 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.